Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Diabetes and obesity fit
2024-04-18

Diabetes and obesity: fit or fat; sugar or not: the autophagic verdict Type 2 diabetes and obesity are among the most emerging health problems worldwide. The factors that are responsible for the establishment of diabetes include decreased DY131 mg production, rise in adiposity, and an increase in
-
PF also a dual Aurora A and Aurora B inhibitor
2024-04-18

PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly FH535 for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the MTD was defined as
-
Exposure to cisplatin with ATR
2024-04-17

Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding indicates that suppressing ATR-Chk1 signaling with VE-822 enhances cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 may incre
-
There are however concerns of potential side effects that
2024-04-17

There are however, concerns of potential side-effects that should also be taken into account. Even though some studies pointed towards a potentially greater radiosensitising effect in p53-deficient tumours, ATM inhibition radiosensitises jak stat in general, which raises the concern of normal tissu
-
The mitogen activated protein kinase
2024-04-17

The mitogen-activated protein kinase (MAPK) plays an important role in a variety of cell processes by controlling transcriptional or translational regulation [14]. There are three major MAPK family members that have been well characterized: extracellular signal-regulated kinase (ERK), c-Jun N-termin
-
As with most G protein coupled receptors GPCRs sustained act
2024-04-17

As with most G protein-coupled receptors (GPCRs), sustained activation of APJ can cause desensitization and this has been reported to occur for APJ-mediated effects on cytoplasmic Ca2+ concentration, as well as for effects on activity of adenylyl cyclase, ERK and Akt (Ishida et al., 2004, Masri et a
-
Protein microarrays represent just one
2024-04-17

Protein microarrays represent just one of a variety of experimental approaches that can be used to generate datasets of relevance to pathway mapping. Other approaches include protein nitric oxide synthase inhibitors profiling techniques, such as antibody arrays [29], tissue arrays [30] and 2-dimensi
-
br Conclusions and perspectives In
2024-04-17

Conclusions and perspectives In view of the evidences supporting that ruthenium red MAS receptors mediate the effects of AT1 antagonists (Iwai et al., 2012, Ohshima et al., 2014, Pernomian et al., 2015, Schuchard et al., 2015), the prime targets from the perspectives on future directions in the
-
Finally intracrine androgen synthesis metabolism can be
2024-04-17

Finally, intracrine androgen synthesis/metabolism can be activated thus allowing Andarine receptor to bypass the low levels of androgens in the circulation by producing androgens themselves (Cai and Balk, 2011, Rahman et al., 2004). Moreover, changes in AR co-regulators like the overexpression of s
-
For patients who have taken advantage of
2024-04-17

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
Interestingly intermittent high doses of AKT inhibitors have
2024-04-17

Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula
-
bepridil Lipotoxicity is the accumulation of excess lipids i
2024-04-17

Lipotoxicity is the accumulation of excess lipids in non-adipose tissues that leads to cell dysfunction or cell death. It may play an important role in the pathogenesis of diabetes, and contributes to the rate of progression of CKD [7,8]. Emerging evidence indicates that renal lipid dysregulation is
-
To our knowledge BAY has
2024-04-17

To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit
-
Because activation of HT A
2024-04-16

Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate rat maternal behavior, especially maternal motivation (Afonso et al., 2007, Febo et al., 2010, Li and Fleming, 2003,
-
Ramelteon br Results and discussion br Conclusion A series o
2024-04-16

Results and discussion Conclusion A series of aminobenzothiazole derivatives were investigated as possible Aurora B kinase inhibitors. Bioisosteric replacement of the heterocyclic core of the lead compound was performed regarding the docking analysis. Replacement of the oxygen Ramelteon of the
16474 records 166/1099 page Previous Next First page 上5页 166167168169170 下5页 Last page